VA Nasonova Scientific Research Institute of Rheumatology

Recent papers from VA Nasonova Scientific Research Institute of Rheumatology

1. Perivascular adipose tissue in stratification of cardiovascular risk in autoimmune inflammation: the current state of the problemRussian Cardiology Bulletin · 2026
2. Surrogate Marker of Vascular Damage in Systemic Lupus ErythematosusAtherosclerosis · 2026
3. Biomarkers of Heart Damage in Patients With Systemic Lupus ErythematosusAtherosclerosis · 2026
4. Determination of the Functional State of the M1-Macrophages in the Blood in Untreated Rheumatoid ArthritisAtherosclerosis · 2026
5. Relationship Between Il-6 Levels and Peripheral Atherosclerosis in Patients With Rheumatoid ArthritisAtherosclerosis · 2026
6. Carotid Atherosclerosis and Immunological Tolerance of Macrophages in Patients With Rheumatoid ArthritisAtherosclerosis · 2026
7. Detection of Neutrophil Extracellular Traps by Flow Cytometry in Healthy Controls and Patients with Systemic Lupus ErythematosusBiomolecules · 2026
8. Resolution of the Expert Council “Non-steroidal anti-inflammatory drugs in the treatment of non-specific back pain and radiculopathy in the 2026 RASP guidelines”Russian Journal of Pain · 2026
9. Granulomatosis with polyangiitis: functional activity of neutrophils and spontaneous NETosis (clinical case)Exploration of Musculoskeletal Diseases · 2026
10. Prospects for the use of new antidiabetic drugs in rheumatologyRheumatology Science and Practice · 2026
11. Features of the disease-modifying antirheumatic drugs for rheumatoid arthritis in men depending on testosterone levelsRussian Journal of Preventive Medicine · 2026
12. Transient constrictive pericarditis associated with COVID-19: a two-year follow-up and treatmentRussian Journal of Cardiology and Cardiovascular Surgery · 2026
13. Batik for disaster communication: a conceptual framework for culturally grounded mitigation media and community resilienceDisaster Prevention and Management An International Journal · 2026
14. Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotypeFrontiers in Immunology · 2026
15. Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label studyArthritis & Rheumatology · 2026
16. Role of disease-modifying drugs in osteoarthritis and pharmaconutraceuticals in the treatment of chronic non-specific back painRussian Journal of Pain · 2026
17. Evaluation of the possibility of using fecal calprotectin for the diagnosis of inflammatory bowel diseases in patients with ankylosing spondylitisMedical alphabet · 2026
18. Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case seriesFrontiers in Medicine · 2026
19. Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Rheumatology and Therapy · 2026
20. Gene Expression Alterations in Peripheral Blood Mononuclear Cells and Cartilage Explants from End-Stage Rheumatoid Arthritis Patients in Response to Taurine: A Pilot Exploratory StudyLife · 2026